What Is Tesamorelin?

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), engineered to resist the rapid breakdown that limits the natural hormone's usefulness as a drug. It is the active ingredient in an FDA-approved product for a single, narrow indication — reducing excess abdominal fat in adults with HIV-associated lipodystrophy — and has been studied separately, in smaller and more preliminary trials, for liver disease and age-related cognitive decline.

What tesamorelin actually is

Structurally, tesamorelin is built from the 44-amino-acid sequence of human GHRH (also called growth hormone-releasing factor, or GRF), with a six-carbon hexenoyl group attached to the N-terminal tyrosine, according to the FDA-approved prescribing information. That modification slows the enzymatic degradation that gives natural GHRH a half-life of only a few minutes in circulation. The finished product is formulated as an acetate salt.

Mechanistically, tesamorelin binds GHRH receptors on somatotroph cells in the anterior pituitary, the same receptors natural GHRH targets, and stimulates pulsatile release of growth hormone. That, in turn, raises circulating insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3) — the two downstream markers researchers typically track to confirm the drug is reaching its target.

Its length also puts it on an interesting regulatory boundary. The FDA generally treats a chain of 40 or fewer amino acids as a "peptide" and anything longer as a protein-based biologic, a line the Journal covered in Peptide vs. Protein: What's the Difference?. At 44 amino acids, tesamorelin sits just over that threshold, which is part of why its FDA application was reclassified from a standard new-drug approval (NDA) to a biologics license (BLA) in March 2020, when a change to federal law moved certain chemically synthesized polypeptide products into the biologic category.

How it reached approval

The company behind tesamorelin, Theratechnologies, ran two multicenter, randomized, placebo-controlled Phase 3 trials enrolling a combined 816 HIV-positive adults with excess abdominal fat before filing for approval in 2009. An FDA advisory committee voted 16 to 0 in favor in May 2010, and the agency approved the product on November 10, 2010, specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy — not for weight loss generally. Theratechnologies has since brought two reformulated versions of the same tesamorelin product to market, in 2019 and 2025, each requiring its own FDA review; the agency's label for the current version states plainly that the formulations are not interchangeable with each other.

The larger of the two pivotal trials, led by Julian Falutz at McGill University and published in the New England Journal of Medicine in 2007, randomized 412 HIV-positive adults with abdominal fat accumulation, 2 to 1, to a once-daily injection of tesamorelin or placebo for 26 weeks. Visceral adipose tissue, measured by CT scan, fell 15.2% in the tesamorelin group and rose 5.0% in the placebo group — a highly significant and selective effect on visceral fat specifically, with little change in subcutaneous fat. Triglycerides dropped by about 50 mg/dL in the treatment group and rose by about 9 mg/dL on placebo. Blood glucose measures didn't differ significantly between groups, but more tesamorelin patients stopped the trial because of side effects than placebo patients did (about 12% versus 3%). That trial, plus a companion study, is the evidence base the FDA approval rests on.

What else has been studied — and in what populations

Tesamorelin's research record extends well past its approved use, though none of that later work has led to an additional FDA indication.

The most developed line of research looks at liver disease in people with HIV. A randomized, double-blind trial led by Takara Stanley and colleagues, published in Lancet HIV in 2019, gave 61 HIV-positive adults with non-alcoholic fatty liver disease either tesamorelin or placebo for 12 months, all adults, all with HIV — not an animal model. Hepatic fat fraction, measured by MRI, fell by an additional 4.1 percentage points in the tesamorelin group relative to placebo, a 37% relative reduction, and 35% of the tesamorelin group reached a normal hepatic fat fraction compared with 4% on placebo. Liver fibrosis was less likely to worsen in the tesamorelin group (about 11% versus 38% on placebo), though the drug did not reverse fibrosis that was already present, and the authors were explicit that the trial wasn't designed or powered to meet the FDA's usual endpoints for a fatty-liver-disease therapy.

A separate, older line of research looked at cognitive aging, again in humans rather than animals. A 2012 trial led by Laura Baker at the University of Washington, published in Archives of Neurology, randomized 152 adults aged 55 to 87 — a mix of people with amnestic mild cognitive impairment and cognitively healthy older adults — to tesamorelin or placebo, self-injected once daily, for 20 weeks. The intent-to-treat analysis found a favorable overall effect on cognition and a statistically significant benefit specifically on executive function, while verbal memory showed only a trend and visual memory showed no effect. The authors' own caveats were extensive: the sample was small for subgroup comparisons, the trial ran only five months, participants were overwhelmingly white and highly educated, side effects were more common on tesamorelin than placebo (68% versus 36%), and the cognitive benefit stopped being statistically detectable once the analysis adjusted for each participant's IGF-1 level — meaning the result is tangled up with the hormonal measure researchers use to confirm the drug is working at all. The authors concluded that "larger and longer-duration treatment trials are needed," and no larger follow-up appears to have been published since.

Regulatory and anti-doping status

Tesamorelin's regulatory story is simpler than that of most compounds the Journal covers, because it isn't a research chemical with an uncertain compounding status — it's an approved drug, just approved for one thing only. The FDA has not approved tesamorelin for liver disease, cognitive aging, or any use beyond reducing excess abdominal fat in HIV-associated lipodystrophy; research into those other areas remains investigational. Material sold outside that approved drug's regulated supply chain carries none of the manufacturing oversight or lot-level accountability the FDA label represents.

In competitive sport, tesamorelin is prohibited outright. The World Anti-Doping Agency's Prohibited List places GHRH and its analogues — naming tesamorelin specifically alongside CJC-1293, CJC-1295 and sermorelin — in category S2, a class banned at all times, in and out of competition, for any tested athlete.

What is known versus unknown

Known: tesamorelin's structure, its receptor-level mechanism, and its effect on visceral fat and triglycerides in HIV-associated lipodystrophy, backed by two Phase 3 trials totaling 816 patients and nearly a decade and a half of post-approval use for that one indication.

Unknown: almost everything about its other studied uses. The liver-disease trial was a single, modestly sized study not designed to meet regulatory endpoints for fatty liver disease, and whether any benefit persists after people stop taking the drug hasn't been tested. The cognitive-aging trial is now over a decade old, was explicitly called preliminary by its own authors, and its central finding weakened once the analysis accounted for IGF-1 — exactly the kind of result that calls for replication before anyone treats it as settled. Long-term cardiovascular and safety data beyond the approved trials' time frames are also limited, since growth-hormone-axis stimulation is a chronic intervention being evaluated mostly in trials measured in months.

What this means for researchers

Tesamorelin is a useful illustration of a distinction that's easy to lose track of: approval for one indication is not evidence for another. The FDA's sign-off reflects two solid trials measuring one outcome — visceral fat — in one population. The liver and cognition research uses the same molecule and the same receptor biology, but each sits on its own, much thinner evidence base, generated by different research groups asking different questions in different populations.

That pattern — a single approved use resting on solid trial data, surrounded by a halo of earlier-stage research into other effects of the same mechanism — is common across the GHRH and growth-hormone-secretagogue research space the Journal covers under /learn. It's worth reading each study for what it actually tested, rather than assuming results in one context carry over to another just because the compound is the same.